Media Highlights

Media Highlights

‘Remarkable’ gene-editing treatment for sickle cell disease is approved by FDA

December 11, 2023

World’s first gene-edited therapy for sickle cell disease shows promise as the first the world’s first gene-edited treatment for sickle cell disease is approved by the FDA, but experts say limitations remain. Dr. Mikkael Sekeres, chief of the division of hematology at Sylvester Comprehensive Cancer Center, weighs in on the potential for CRISPR technology in the treatment of sickle cell disease.

Read the Full article

Tags:   Sylvester Comprehensive Cancer Center